{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:17:59Z","timestamp":1790360279807,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-03089-3","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:25:53Z","timestamp":1784028353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Parkinson\u2019s disease as a multi-axis systems disorder: integrating molecular pathology and circuit-level therapeutics"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9826-3137","authenticated-orcid":false,"given":"Duc-Hiep","family":"Bach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh Liem","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"7","key":"3089_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJM196902132800701","volume":"280","author":"GC Cotzias","year":"1969","unstructured":"Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism\u2013chronic treatment with L-dopa. N Engl J Med. 1969;280(7):337\u201345.","journal-title":"N Engl J Med"},{"issue":"10423","key":"3089_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson\u2019s disease. Lancet. 2024;403(10423):293\u2013304.","journal-title":"Lancet"},{"issue":"5","key":"3089_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, et al. Trial of Cinpanemab in Early Parkinson\u2019s Disease. N Engl J Med. 2022;387(5):408\u201320.","journal-title":"N Engl J Med"},{"issue":"5","key":"3089_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, et al. Trial of Prasinezumab in Early-Stage Parkinson\u2019s Disease. N Engl J Med. 2022;387(5):421\u201332.","journal-title":"N Engl J Med"},{"issue":"12","key":"3089_CR5","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1038\/s41591-024-03270-6","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, Simuni T, Postuma RB, Pavese N, Stocchi F, et al. Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024;30(12):3669\u201375.","journal-title":"Nat Med"},{"issue":"1","key":"3089_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41531-021-00203-9","volume":"7","author":"LMA Oliveira","year":"2021","unstructured":"Oliveira LMA, Gasser T, Edwards R, Zweckstetter M, Melki R, Stefanis L, Lashuel HA, Sulzer D, Vekrellis K, Halliday GM, et al. Alpha-synuclein research: defining strategic moves in the battle against Parkinson\u2019s disease. npj Parkinson\u2019s Disease. 2021;7(1):65.","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"41","key":"3089_CR7","doi-asserted-by":"publisher","first-page":"9808","DOI":"10.1523\/JNEUROSCI.1788-16.2017","volume":"37","author":"P Brundin","year":"2017","unstructured":"Brundin P, Melki R. Prying into the Prion Hypothesis for Parkinson\u2019s Disease. J Neurosci. 2017;37(41):9808\u201318.","journal-title":"J Neurosci"},{"key":"3089_CR8","doi-asserted-by":"publisher","first-page":"107208","DOI":"10.1016\/j.parkreldis.2024.107208","volume":"130","author":"X Deng","year":"2025","unstructured":"Deng X, Mehta A, Xiao B, Ray Chaudhuri K, Tan EK, Tan LC. Parkinson\u2019s disease subtypes: Approaches and clinical implications. Parkinsonism Relat Disord. 2025;130:107208.","journal-title":"Parkinsonism Relat Disord"},{"issue":"8064","key":"3089_CR9","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41586-025-08845-y","volume":"641","author":"V Tabar","year":"2025","unstructured":"Tabar V, Sarva H, Lozano AM, Fasano A, Kalia SK, Yu KKH, Brennan C, Ma Y, Peng S, Eidelberg D, et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson\u2019s disease. Nature. 2025;641(8064):978\u201383.","journal-title":"Nature"},{"issue":"2","key":"3089_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.stem.2021.01.004","volume":"28","author":"J Piao","year":"2021","unstructured":"Piao J, Zabierowski S, Dubose BN, Hill EJ, Navare M, Claros N, Rosen S, Ramnarine K, Horn C, Fredrickson C, et al. Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. Cell Stem Cell. 2021;28(2):217\u2013e229217.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"3089_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41593-019-0541-x","volume":"23","author":"A Lau","year":"2020","unstructured":"Lau A, So RWL, Lau HHC, Sang JC, Ruiz-Riquelme A, Fleck SC, Stuart E, Menon S, Visanji NP, Meisl G, et al. \u03b1-Synuclein strains target distinct brain regions and cell types. Nat Neurosci. 2020;23(1):21\u201331.","journal-title":"Nat Neurosci"},{"issue":"2","key":"3089_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong YC, Krainc D. \u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017;23(2):1\u201313.","journal-title":"Nat Med"},{"issue":"5","key":"3089_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41593-022-01061-1","volume":"25","author":"T Kamath","year":"2022","unstructured":"Kamath T, Abdulraouf A, Burris SJ, Langlieb J, Gazestani V, Nadaf NM, Balderrama K, Vanderburg C, Macosko EZ. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson\u2019s disease. Nat Neurosci. 2022;25(5):588\u201395.","journal-title":"Nat Neurosci"},{"issue":"1","key":"3089_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41392-022-00983-3","volume":"7","author":"M Vos","year":"2022","unstructured":"Vos M. Mitochondrial Complex I deficiency: guilty in Parkinson\u2019s disease. Signal Transduct Target Therapy. 2022;7(1):136.","journal-title":"Signal Transduct Target Therapy"},{"issue":"7886","key":"3089_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41586-021-04059-0","volume":"599","author":"P Gonz\u00e1lez-Rodr\u00edguez","year":"2021","unstructured":"Gonz\u00e1lez-Rodr\u00edguez P, Zampese E, Stout KA, Guzman JN, Ilijic E, Yang B, Tkatch T, Stavarache MA, Wokosin DL, Gao L, et al. Disruption of mitochondrial complex I induces progressive parkinsonism. Nature. 2021;599(7886):650\u20136.","journal-title":"Nature"},{"issue":"3","key":"3089_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1471-4159.1990.tb02325.x","volume":"54","author":"AH Schapira","year":"1990","unstructured":"Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson\u2019s disease. J Neurochem. 1990;54(3):823\u20137.","journal-title":"J Neurochem"},{"issue":"17","key":"3089_CR17","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361(17):1651\u201361.","journal-title":"N Engl J Med"},{"issue":"10","key":"3089_CR18","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/mds.26797","volume":"31","author":"LR Kett","year":"2016","unstructured":"Kett LR, Dauer WT. Endolysosomal dysfunction in Parkinson\u2019s disease: Recent developments and future challenges. Mov Disord. 2016;31(10):1433\u201343.","journal-title":"Mov Disord"},{"key":"3089_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fcell.2017.00110","volume":"5","author":"N Plotegher","year":"2017","unstructured":"Plotegher N, Duchen MR. Crosstalk between Lysosomes and Mitochondria in Parkinson\u2019s Disease. Front Cell Dev Biol. 2017;5:110.","journal-title":"Front Cell Dev Biol"},{"key":"3089_CR20","doi-asserted-by":"crossref","unstructured":"Steger M, Diez F, Dhekne HS, Lis P, Nirujogi RS, Karayel O, Tonelli F, Martinez TN, Lorentzen E, Pfeffer SR et al. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife 2017; 6.","DOI":"10.7554\/eLife.31012"},{"issue":"11","key":"3089_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657\u201373.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3089_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mds.28411","volume":"36","author":"EM Kline","year":"2021","unstructured":"Kline EM, Houser MC, Herrick MK, Seibler P, Klein C, West A, Tansey MG. Genetic and Environmental Factors in Parkinson\u2019s Disease Converge on Immune Function and Inflammation. Mov Disord. 2021;36(1):25\u201336.","journal-title":"Mov Disord"},{"issue":"9","key":"3089_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.neurol.2025.06.012","volume":"181","author":"L Grass","year":"2025","unstructured":"Grass L, Grimaldi S, Damier P. Prodromal Parkinson\u2019s disease. Rev Neurol. 2025;181(9):863\u201380.","journal-title":"Rev Neurol"},{"key":"3089_CR24","doi-asserted-by":"publisher","first-page":"1113889","DOI":"10.3389\/fnins.2023.1113889","volume":"17","author":"L Jiang","year":"2023","unstructured":"Jiang L, Zhuo J, Furman A, Fishman PS, Gullapalli R. Cerebellar functional connectivity change is associated with motor and neuropsychological function in early stage drug-na\u00efve patients with Parkinson\u2019s disease. Front Neurosci. 2023;17:1113889.","journal-title":"Front Neurosci"},{"issue":"3","key":"3089_CR25","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awz030","volume":"142","author":"RB Postuma","year":"2019","unstructured":"Postuma RB, Iranzo A, Hu M, H\u00f6gl B, Boeve BF, Manni R, Oertel WH, Arnulf I, Ferini-Strambi L, Puligheddu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142(3):744\u201359.","journal-title":"Brain"},{"key":"3089_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/bs.pbr.2020.02.005","volume":"252","author":"P Gonzalez-Rodriguez","year":"2020","unstructured":"Gonzalez-Rodriguez P, Zampese E, Surmeier DJ. Selective neuronal vulnerability in Parkinson\u2019s disease. Prog Brain Res. 2020;252:61\u201389.","journal-title":"Prog Brain Res"},{"issue":"10","key":"3089_CR27","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1093\/brain\/awz239","volume":"142","author":"A Horn","year":"2019","unstructured":"Horn A, Wenzel G, Irmen F, Huebl J, Li N, Neumann WJ, Krause P, Bohner G, Scheel M, K\u00fchn AA. Deep brain stimulation induced normalization of the human functional connectome in Parkinson\u2019s disease. Brain. 2019;142(10):3129\u201343.","journal-title":"Brain"},{"issue":"7","key":"3089_CR28","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/hbm.23594","volume":"38","author":"A Horn","year":"2017","unstructured":"Horn A, Neumann WJ, Degen K, Schneider GH, K\u00fchn AA. Toward an electrophysiological sweet spot for deep brain stimulation in the subthalamic nucleus. Hum Brain Mapp. 2017;38(7):3377\u201390.","journal-title":"Hum Brain Mapp"},{"issue":"8","key":"3089_CR29","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/mds.27376","volume":"33","author":"F Lipsmeier","year":"2018","unstructured":"Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A, Schjodt-Eriksen J, Cheng WY, Fernandez-Garcia I, Siebourg-Polster J, Jin L, et al. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson\u2019s disease clinical trial. Mov Disord. 2018;33(8):1287\u201397.","journal-title":"Mov Disord"},{"issue":"12","key":"3089_CR30","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601.","journal-title":"Mov Disord"},{"issue":"5","key":"3089_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"JY Li","year":"2008","unstructured":"Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bj\u00f6rklund A, et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501\u20133.","journal-title":"Nat Med"},{"issue":"3","key":"3089_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.10720","volume":"54","author":"CW Olanow","year":"2003","unstructured":"Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease. Ann Neurol. 2003;54(3):403\u201314.","journal-title":"Ann Neurol"},{"issue":"128","key":"3089_CR33","doi-asserted-by":"publisher","first-page":"128ra141","DOI":"10.1126\/scitranslmed.3003391","volume":"4","author":"M Politis","year":"2012","unstructured":"Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Bj\u00f6rklund A, Lindvall O, Piccini P. Serotonin neuron loss and nonmotor symptoms continue in Parkinson\u2019s patients treated with dopamine grafts. Sci Transl Med. 2012;4(128):128ra141.","journal-title":"Sci Transl Med"},{"issue":"4","key":"3089_CR34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch EC, Hunot S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382\u201397.","journal-title":"Lancet Neurol"},{"issue":"4","key":"3089_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JPD-130230","volume":"3","author":"V Dias","year":"2013","unstructured":"Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson\u2019s disease. J Parkinsons Dis. 2013;3(4):461\u201391.","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"3089_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ceca.2009.12.003","volume":"47","author":"DJ Surmeier","year":"2010","unstructured":"Surmeier DJ, Guzman JN, Sanchez-Padilla J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson\u2019s disease. Cell Calcium. 2010;47(2):175\u201382.","journal-title":"Cell Calcium"},{"issue":"7","key":"3089_CR37","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41591-019-0507-2","volume":"25","author":"RA Barker","year":"2019","unstructured":"Barker RA, Farrell K, Guzman NV, He X, Lazic SE, Moore S, Morris R, Tyers P, Wijeyekoon R, Daft D, et al. Designing stem-cell-based dopamine cell replacement trials for Parkinson\u2019s disease. Nat Med. 2019;25(7):1045\u201353.","journal-title":"Nat Med"},{"issue":"20","key":"3089_CR38","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, Jeon J, Cha Y, Kim K, Li Q, et al. Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson\u2019s Disease. N Engl J Med. 2020;382(20):1926\u201332.","journal-title":"N Engl J Med"},{"issue":"8064","key":"3089_CR39","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","volume":"641","author":"N Sawamoto","year":"2025","unstructured":"Sawamoto N, Doi D, Nakanishi E, Sawamura M, Kikuchi T, Yamakado H, Taruno Y, Shima A, Fushimi Y, Okada T, et al. Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson\u2019s disease. Nature. 2025;641(8064):971\u20137.","journal-title":"Nature"},{"issue":"23","key":"3089_CR40","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.1073\/pnas.1605245113","volume":"113","author":"W Li","year":"2016","unstructured":"Li W, Englund E, Widner H, Mattsson B, van Westen D, L\u00e4tt J, Rehncrona S, Brundin P, Bj\u00f6rklund A, Lindvall O, et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A. 2016;113(23):6544\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3089_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435\u201350.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"3089_CR42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/ejn.14290","volume":"49","author":"MG Tansey","year":"2019","unstructured":"Tansey MG, Romero-Ramos M. Immune system responses in Parkinson\u2019s disease: Early and dynamic. Eur J Neurosci. 2019;49(3):364\u201383.","journal-title":"Eur J Neurosci"},{"issue":"7825","key":"3089_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","volume":"585","author":"M Schweighauser","year":"2020","unstructured":"Schweighauser M, Shi Y, Tarutani A, Kametani F, Murzin AG, Ghetti B, Matsubara T, Tomita T, Ando T, Hasegawa K, et al. Structures of \u03b1-synuclein filaments from multiple system atrophy. Nature. 2020;585(7825):464\u20139.","journal-title":"Nature"},{"issue":"1","key":"3089_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","volume":"72","author":"LA Volpicelli-Daley","year":"2011","unstructured":"Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM. Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72(1):57\u201371.","journal-title":"Neuron"},{"issue":"7378","key":"3089_CR45","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10648","volume":"480","author":"S Kriks","year":"2011","unstructured":"Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson\u2019s disease. Nature. 2011;480(7378):547\u201351.","journal-title":"Nature"},{"issue":"s1","key":"3089_CR46","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.3233\/JPD-179006","volume":"7","author":"JW Langston","year":"2017","unstructured":"Langston JW. The MPTP Story. J Parkinsons Dis. 2017;7(s1):S11\u20139.","journal-title":"J Parkinsons Dis"},{"issue":"7324","key":"3089_CR47","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/nature09536","volume":"468","author":"JN Guzman","year":"2010","unstructured":"Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT, Surmeier DJ. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature. 2010;468(7324):696\u2013700.","journal-title":"Nature"},{"issue":"7479","key":"3089_CR48","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nature12748","volume":"504","author":"SA Hasson","year":"2013","unstructured":"Hasson SA, Kane LA, Yamano K, Huang C-H, Sliter DA, Buehler E, Wang C, Heman-Ackah SM, Hessa T, Guha R, et al. High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. Nature. 2013;504(7479):291\u20135.","journal-title":"Nature"},{"issue":"7113","key":"3089_CR49","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"MT Lin","year":"2006","unstructured":"Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787\u201395.","journal-title":"Nature"},{"issue":"10","key":"3089_CR50","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.celrep.2018.05.009","volume":"23","author":"DC Sch\u00f6ndorf","year":"2018","unstructured":"Sch\u00f6ndorf DC, Ivanyuk D, Baden P, Sanchez-Martinez A, De Cicco S, Yu C, Giunta I, Schwarz LK, Di Napoli G, Panagiotakopoulou V, et al. The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson\u2019s Disease. Cell Rep. 2018;23(10):2976\u201388.","journal-title":"Cell Rep"},{"issue":"5","key":"3089_CR51","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","volume":"71","author":"MF Beal","year":"2014","unstructured":"Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543\u201352.","journal-title":"JAMA Neurol"},{"issue":"10","key":"3089_CR52","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jama.2021.10207","volume":"326","author":"MA Schwarzschild","year":"2021","unstructured":"Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, Kamp C, Lungu C, Macklin EA, Marek K, Mozaffarian D, et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021;326(10):926\u201339.","journal-title":"JAMA"},{"issue":"4","key":"3089_CR53","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K, D\u2019Souza G, Woodgate P, Elflein J, H\u00e4llqvist J, Toffoli M, Streeter A, Hosking J, et al. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol. 2020;77(4):427\u201334.","journal-title":"JAMA Neurol"},{"issue":"648","key":"3089_CR54","doi-asserted-by":"publisher","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci Transl Med. 2022;14(648):eabj2658.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3089_CR55","first-page":"182","volume":"119","author":"V Brochard","year":"2009","unstructured":"Brochard V, Combadi\u00e8re B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, et al. Infiltration of CD4\u2009+\u2009lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119(1):182\u201392.","journal-title":"J Clin Invest"},{"issue":"1","key":"3089_CR56","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1038\/s41467-019-13413-w","volume":"10","author":"D Ysselstein","year":"2019","unstructured":"Ysselstein D, Nguyen M, Young TJ, Severino A, Schwake M, Merchant K, Krainc D. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson\u2019s disease patients. Nat Commun. 2019;10(1):5570.","journal-title":"Nat Commun"},{"issue":"8","key":"3089_CR57","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(15)00144-1","volume":"14","author":"Pioglitazone","year":"2015","unstructured":"Pioglitazone. early Parkinson\u2019s disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015;14(8):795\u2013803.","journal-title":"Lancet Neurol"},{"key":"3089_CR58","doi-asserted-by":"crossref","unstructured":"A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66(5):664\u2013671.","DOI":"10.1212\/01.wnl.0000201252.57661.e1"},{"issue":"1","key":"3089_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146(1):37\u201352.","journal-title":"Cell"},{"key":"3089_CR60","doi-asserted-by":"crossref","unstructured":"D\u00f6lle C, Tzoulis C. NAD augmentation as a disease-modifying strategy for neurodegeneration. Trends Endocrinol Metabolism 2025.","DOI":"10.1016\/j.tem.2025.03.013"},{"issue":"10","key":"3089_CR61","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","volume":"59","author":"CW Shults","year":"2002","unstructured":"Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541\u201350.","journal-title":"Arch Neurol"},{"issue":"3","key":"3089_CR62","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13534-022-00226-y","volume":"12","author":"A Malvea","year":"2022","unstructured":"Malvea A, Babaei F, Boulay C, Sachs A, Park J. Deep brain stimulation for Parkinson\u2019s Disease: A Review and Future Outlook. Biomed Eng Lett. 2022;12(3):303\u201316.","journal-title":"Biomed Eng Lett"},{"issue":"1","key":"3089_CR63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ana.24974","volume":"82","author":"A Horn","year":"2017","unstructured":"Horn A, Reich M, Vorwerk J, Li N, Wenzel G, Fang Q, Schmitz-H\u00fcbsch T, Nickl R, Kupsch A, Volkmann J, et al. Connectivity Predicts deep brain stimulation outcome in Parkinson disease. Ann Neurol. 2017;82(1):67\u201378.","journal-title":"Ann Neurol"},{"issue":"9","key":"3089_CR64","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nrneurol.2015.123","volume":"11","author":"RA Barker","year":"2015","unstructured":"Barker RA, Drouin-Ouellet J, Parmar M. Cell-based therapies for Parkinson disease\u2014past insights and future potential. Nat Rev Neurol. 2015;11(9):492\u2013503.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"3089_CR65","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.brs.2024.02.005","volume":"17","author":"EJ Lee","year":"2024","unstructured":"Lee EJ, Aguirre-Padilla DH, Fomenko A, Pawar G, Kapadia M, George J, Lozano AM, Hamani C, Kalia LV, Kalia SK. Reduction of alpha-synuclein oligomers in preclinical models of Parkinson\u2019s disease by electrical stimulation in vitro and deep brain stimulation in vivo. Brain Stimul. 2024;17(2):166\u201375.","journal-title":"Brain Stimul"},{"issue":"38","key":"3089_CR66","doi-asserted-by":"publisher","first-page":"e08503","DOI":"10.1002\/advs.202408503","volume":"12","author":"S Zhou","year":"2025","unstructured":"Zhou S, Xiong X, Hou J, Duan Q, Zheng Y, Jiang T, Huang J, He H, Xu J, Chen K, et al. NAD+-Boosters Improve Mitochondria Quality Control In Parkinson\u2019s Disease Models Via Mitochondrial UPR. Adv Sci (Weinh). 2025;12(38):e08503.","journal-title":"Adv Sci (Weinh)"},{"issue":"8","key":"3089_CR67","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi N, Alcalay RN, Cutter G, Gasser T, Gurevich T, H\u00f6glinger GU, Marek K, Pacchetti C, Schapira AHV, Scherzer CR, et al. Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2023;22(8):661\u201371.","journal-title":"Lancet Neurol"},{"issue":"3","key":"3089_CR68","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mds.29297","volume":"38","author":"D Jennings","year":"2023","unstructured":"Jennings D, Huntwork-Rodriguez S, Vissers MFJM, Daryani VM, Diaz D, Goo MS, Chen JJ, Maciuca R, Fraser K, Mabrouk OS, et al. LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson\u2019s Disease. Mov Disord. 2023;38(3):386\u201398.","journal-title":"Mov Disord"},{"issue":"7","key":"3089_CR69","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/brain\/awx118","volume":"140","author":"S-M Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad S-M, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson\u2019s disease: biomarkers and longitudinal progression. Brain. 2017;140(7):1959\u201376.","journal-title":"Brain"},{"issue":"11","key":"3089_CR70","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1212\/WNL.0000000000009107","volume":"94","author":"AJ Espay","year":"2020","unstructured":"Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. 2020;94(11):481\u201394.","journal-title":"Neurology"},{"issue":"2","key":"3089_CR71","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178\u201390.","journal-title":"Lancet Neurol"},{"issue":"2","key":"3089_CR72","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, Postuma R, Stoessl AJ, Lang AE. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23(2):191\u2013204.","journal-title":"Lancet Neurol"},{"issue":"3","key":"3089_CR73","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mds.26913","volume":"32","author":"AJ Espay","year":"2017","unstructured":"Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, et al. Biomarker-driven phenotyping in Parkinson\u2019s disease: A translational missing link in disease-modifying clinical trials. Mov Disord. 2017;32(3):319\u201324.","journal-title":"Mov Disord"},{"key":"3089_CR74","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"3089_CR75","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021;7(1):47.","journal-title":"Nat Rev Dis Primers"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-03089-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03089-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03089-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:03:38Z","timestamp":1790244218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-03089-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3089"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-03089-3","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"507"}}